Jeroen van Velzen

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

Inger S. Nijhof, Tineke Casneuf, Jeroen van Velzen et al. · Blood · 2016 · 380 citations · Full text

Life Sciences, Immunology, Oncology +13

Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab

Inger S. Nijhof, Richard W.J. Groen, H M Lokhorst et al. · Leukemia · 2015 · 266 citations · Full text

Medicine, Immunology, Pharmacology +17

Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma

Inger S. Nijhof, Laurens E. Franssen, Mark‐David Levin et al. · Blood · 2016 · 56 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients

Laurens E. Franssen, Inger S. Nijhof, Chad C. Bjorklund et al. · Oncotarget · 2018 · 20 citations · Full text

Medicine, Hematology, Immunology +17